Surviving apoptosis: Life-death signaling in single cells

Trends in Cell Biology

Volumn 25, Issue 8, 2015, Pages 446-458

  Flusberg, Deborah A ^a   Sorger, Peter K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; Cell fate; Death ligand; Life death decision; Survival; Variability

Indexed keywords

DEATH RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; CELL DEATH; CELL DIFFERENTIATION; CELL FATE; CELL KILLING; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; EMBRYO DEVELOPMENT; HUMAN; PRIORITY JOURNAL; REVIEW; SINGLE CELL ANALYSIS; ANIMAL; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL DEATH; CELL SURVIVAL; HUMANS; RECEPTORS, DEATH DOMAIN; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84937735960     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2015.03.003     Document Type: Review

References (185)

1. Brock A., et al. Non-genetic heterogeneity: a mutation-independent driving force for the somatic evolution of tumours. Nat. Rev. Genet. 2009, 10:336-342.
2. Eldar A., Elowitz M.B. Functional roles for noise in genetic circuits. Nature 2010, 467:167-173.
3. Raj A., van Oudenaarden A. Nature, nurture, or chance: stochastic gene expression and its consequences. Cell 2008, 135:216-226.
4. Beere H.M. Death versus survival: functional interaction between the apoptotic and stress-inducible heat shock protein pathways. J. Clin. Invest. 2005, 115:2633-2639.
5. Carvajal L.A., Manfredi J.J. Another fork in the road: life or death decisions by the tumour suppressor p53. EMBO Rep. 2013, 14:414-421.
6. Marino G., et al. Self-consumption: the interplay of autophagy and apoptosis. Nat. Rev. 2014, 15:81-94.
7. Yuan J. Divergence from a dedicated cellular suicide mechanism: exploring the evolution of cell death. Mol. Cell 2006, 23:1-12.
8. Munoz-Pinedo C. Signaling pathways that regulate life and cell death: evolution of apoptosis in the context of self-defense. Adv. Exp. Med. Biol. 2012, 738:124-143.
9. Kuranaga E. Caspase signaling in animal development. Dev. Growth Differ. 2011, 53:137-148.
10. Sola S., et al. Driving apoptosis-relevant proteins toward neural differentiation. Mol. Neurobiol. 2012, 46:316-331.
11. Losick R., Desplan C. Stochasticity and cell fate. Science 2008, 320:65-68.
12. Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev. 2008, 19:325-331.
13. Guicciardi M.E., Gores G.J. Life and death by death receptors. FASEB J. 2009, 23:1625-1637.
14. Malhi H., Gores G.J. TRAIL resistance results in cancer progression: a TRAIL to perdition?. Oncogene 2006, 25:7333-7335.
15. Wilson N.S., et al. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat. Immunol. 2009, 10:348-355.
16. Feig C., et al. Palmitoylation of CD95 facilitates formation of SDS-stable receptor aggregates that initiate apoptosis signaling. EMBO J. 2007, 26:221-231.
17. Mazurek N., et al. Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells. Cell Death Differ. 2011, 19:523-533.
18. Rossin A., et al. Palmitoylation of the TRAIL receptor DR4 confers an efficient TRAIL-induced cell death signalling. Biochem. J. 2009, 419:185-192.
19. Wagner K.W., et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med. 2007, 13:1070-1077.
20. Gonzalvez F., Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 2010, 29:4752-4765.
21. Lu M., et al. E-cadherin couples death receptors to the cytoskeleton to regulate apoptosis. Mol. Cell 2014, 54:987-998.
22. Merino D., et al. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol. Cell. Biol. 2006, 26:7046-7055.
23. Muppidi J.R., et al. Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity 2004, 21:461-465.
24. Neumann L., et al. Dynamics within the CD95 death-inducing signaling complex decide life and death of cells. Mol. Syst. Biol. 2010, 6:352.
25. Peter M.E., Krammer P.H. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 2003, 10:26-35.
26. Micheau O., et al. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J. Biol. Chem. 2002, 277:45162-45171.
27. Chang D.W., et al. c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J. 2002, 21:3704-3714.
28. Chipuk J.E., Green D.R. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?. Trends Cell Biol. 2008, 18:157-164.
29. Letai A., et al. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002, 2:183-192.
30. Albeck J.G., et al. Quantitative analysis of pathways controlling extrinsic apoptosis in single cells. Mol. Cell 2008, 30:11-25.
31. Aldridge B.B., et al. Lyapunov exponents and phase diagrams reveal multi-factorial control over TRAIL-induced apoptosis. Mol. Syst. Biol. 2011, 7:553.
32. Jost P.J., et al. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 2009, 460:1035-1039.
33. Gaudet S., et al. Exploring the contextual sensitivity of factors that determine cell-to-cell variability in receptor-mediated apoptosis. PLoS Comput. Biol. 2012, 8:e1002482.
34. Passante E., et al. Systems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells. Cell Death Differ. 2013, 20:1521-1531.
35. Walczak H. Death receptor-ligand systems in cancer, cell death, and inflammation. Cold Spring Harb. Perspect. Biol. 2013, 5:a008698.
36. Jin Z., El-Deiry W.S. Distinct signaling pathways in TRAIL- versus tumor necrosis factor-induced apoptosis. Mol. Cell. Biol. 2006, 26:8136-8148.
37. Varfolomeev E., et al. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J. Biol. Chem. 2005, 280:40599-40608.
38. Wajant H., et al. Non-apoptotic Fas signaling. Cytokine Growth Factor Rev. 2003, 14:53-66.
39. Barnhart B.C., et al. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J. 2004, 23:3175-3185.
40. Flusberg D.A., et al. Cells surviving fractional killing by TRAIL exhibit transient but sustainable resistance and inflammatory phenotypes. Mol. Biol. Cell 2013, 24:2186-2200.
41. Hu W.H., et al. Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways. J. Biol. Chem. 1999, 274:30603-30610.
42. Ishimura N., et al. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290:G129-G136.
43. Yurchenko M., et al. The multilevel regulation of CD95 signaling outcome. Exp. Oncol. 2012, 34:153-159.
44. Desbarats J., Newell M.K. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat. Med. 2000, 6:920-923.
45. Zuliani C., et al. Control of neuronal branching by the death receptor CD95 (Fas/Apo-1). Cell Death Differ. 2006, 13:31-40.
46. Freer-Prokop M., et al. Non-canonical role for the TRAIL receptor DR5/FADD/caspase pathway in the regulation of MyoD expression and skeletal myoblast differentiation. Differentiation 2009, 78:205-212.
47. Rimondi E., et al. Involvement of TRAIL/TRAIL-receptors in human intestinal cell differentiation. J. Cell. Physiol. 2006, 206:647-654.
48. Secchiero P., Zauli G. Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr. Opin. Hematol. 2008, 15:42-48.
49. Secchiero P., et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 2003, 107:2250-2256.
50. Secchiero P., et al. TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell. Mol. Life Sci. 2004, 61:1965-1974.
51. Cantarella G., et al. Involvement of caspase 8 and c-FLIPL in the proangiogenic effects of the tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). FEBS J. 2014, 281:1505-1513.
52. Kleber S., et al. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 2008, 13:235-248.
53. Chen L., et al. CD95 promotes tumour growth. Nature 2010, 465:492-496.
54. Ehrhardt H., et al. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 2003, 22:3842-3852.
55. Kim J.H., et al. TRAIL induces MMP-9 expression via ERK activation in human astrocytoma cells. Biochem. Biophys. Res. Commun. 2008, 377:195-199.
56. Pavet V., et al. Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells. Cell Death Dis. 2014, 5:e1043.
57. Trauzold A., et al. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 2006, 25:7434-7439.
58. Zhou D.H., et al. The potential molecular mechanism of overexpression of uPA, IL-8, MMP-7 and MMP-9 induced by TRAIL in pancreatic cancer cell. Hepatobiliary Pancreat. Dis. Int. 2008, 7:201-209.
59. Azijli K., et al. Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family. Cell Death Differ. 2013, 20:858-868.
60. Christofferson D.E., et al. Control of life-or-death decisions by RIP1 kinase. Annu. Rev. Physiol. 2014, 76:129-150.
61. Dickens L.S., et al. The 'complexities' of life and death: death receptor signalling platforms. Exp. Cell Res. 2012, 318:1269-1277.
62. Micheau O., Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003, 114:181-190.
63. Holler N., et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat. Immunol. 2000, 1:489-495.
64. Austin C.D., et al. Death-receptor activation halts clathrin-dependent endocytosis. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:10283-10288.
65. Kohlhaas S.L., et al. Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. J. Biol. Chem. 2007, 282:12831-12841.
66. Song J.H., et al. Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. Cancer Res. 2007, 67:6946-6955.
67. Lavrik I.N., et al. Analysis of CD95 threshold signaling: triggering of CD95 (FAS/APO-1) at low concentrations primarily results in survival signaling. J. Biol. Chem. 2007, 282:13664-13671.
68. Legembre P., et al. Induction of apoptosis and activation of NF-kappaB by CD95 require different signalling thresholds. EMBO Rep. 2004, 5:1084-1089.
69. LA O.R., et al. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 2009, 461:659-663.
70. Fricker N., et al. Model-based dissection of CD95 signaling dynamics reveals both a pro- and antiapoptotic role of c-FLIPL. J. Cell Biol. 2010, 190:377-389.
71. Azijli K., et al. MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1. Apoptosis 2013, 18:851-860.
72. Son J.K., et al. TRAIL-activated stress kinases suppress apoptosis through transcriptional upregulation of MCL-1. Cell Death Differ. 2010, 17:1288-1301.
73. Gonzalvez F., et al. TRAF2 Sets a threshold for extrinsic apoptosis by tagging caspase-8 with a ubiquitin shutoff timer. Mol. Cell 2012, 48:888-899.
74. Jin Z., et al. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 2009, 137:721-735.
75. Dickens L.S., et al. A death effector domain chain DISC model reveals a crucial role for caspase-8 chain assembly in mediating apoptotic cell death. Mol. Cell 2012, 47:291-305.
76. Schleich K., et al. Stoichiometry of the CD95 death-inducing signaling complex: experimental and modeling evidence for a death effector domain chain model. Mol. Cell 2012, 47:306-319.
77. Hughes M.A., et al. Reconstitution of the death-inducing signaling complex reveals a substrate switch that determines CD95-mediated death or survival. Mol. Cell 2009, 35:265-279.
78. Kallenberger S.M., et al. Intra- and interdimeric caspase-8 self-cleavage controls strength and timing of CD95-induced apoptosis. Sci. Signal. 2014, 7:ra23.
79. Spencer S.L., et al. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 2009, 459:428-432.
80. Falschlehner C., et al. TRAIL signalling: decisions between life and death. Int. J. Biochem. Cell Biol. 2007, 39:1462-1475.
81. Marusyk A., et al. Intra-tumour heterogeneity: a looking glass for cancer?. Nat. Rev. Cancer 2012, 12:323-334.
82. Bhola P.D., Simon S.M. Determinism and divergence of apoptosis susceptibility in mammalian cells. J. Cell Sci. 2009, 122:4296-4302.
83. Rehm M., et al. Dynamics of outer mitochondrial membrane permeabilization during apoptosis. Cell Death Differ. 2009, 16:613-623.
84. Flusberg D.A., Sorger P.K. Modulating cell-to-cell variability and sensitivity to death ligands by co-drugging. Phys. Biol. 2013, 10:035002.
85. Bertaux F., et al. Modeling dynamics of cell-to-cell variability in TRAIL-induced apoptosis explains fractional killing and predicts reversible resistance. PLoS Comput. Biol. 2014, 10:e1003893.
86. Tang W., et al. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced chemokine release in both TRAIL-resistant and TRAIL-sensitive cells via nuclear factor kappa B. FEBS J. 2009, 276:581-593.
87. Zauli G., et al. PI-3K/Akt and NF-kappaB/IkappaBalpha pathways are activated in Jurkat T cells in response to TRAIL treatment. J. Cell. Physiol. 2005, 202:900-911.
88. Cohen A.A., et al. Dynamic proteomics of individual cancer cells in response to a drug. Science 2008, 322:1511-1516.
89. Muranen T., et al. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 2012, 21:227-239.
90. Lee H.J., et al. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 2014, 26:207-221.
91. Raha D., et al. The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation. Cancer Res. 2014, 74:3579-3590.
92. Roesch A., et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010, 141:583-594.
93. Sabnis G.J., et al. Stopping treatment can reverse acquired resistance to letrozole. Cancer Res. 2008, 68:4518-4524.
94. Sharma S.V., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
95. Sun C., et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 2014, 508:118-122.
96. Kurbanov B.M., et al. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Oncogene 2007, 26:3364-3377.
97. Song J.J., et al. Evidence for two modes of development of acquired tumor necrosis factor-related apoptosis-inducing ligand resistance. Involvement of Bcl-Xl. J. Biol. Chem. 2007, 282:319-328.
98. Song J.J., et al. c-Cbl acts as a mediator of Src-induced activation of the PI3K-Akt signal transduction pathway during TRAIL treatment. Cell Signal. 2009, 22:377-385.
99. Chakrabarti L., et al. Reversible adaptive plasticity: a mechanism for neuroblastoma cell heterogeneity and chemo-resistance. Front. Oncol. 2012, 2:82.
100. Fallahi-Sichani M., et al. Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat. Chem. Biol. 2013, 9:708-714.
101. Wilson T.R., et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487:505-509.
102. Xia X., et al. Cell-to-cell variability in cell death: can systems biology help us make sense of it all?. Cell Death Dis. 2014, 5:e1261.
103. Acar M., et al. Enhancement of cellular memory by reducing stochastic transitions. Nature 2005, 435:228-232.
104. Bodenmiller B., et al. Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nat. Biotechnol. 2012, 30:858-867.
105. Farkash-Amar S., et al. Noise genetics: inferring protein function by correlating phenotype with protein levels and localization in individual human cells. PLoS Genet. 2014, 10:e1004176.
106. Janes K.A., et al. Identifying single-cell molecular programs by stochastic profiling. Nat. Methods 2010, 7:311-317.
107. Sigal A., et al. Variability and memory of protein levels in human cells. Nature 2006, 444:643-646.
108. Marriott H.M., et al. Dynamic changes in Mcl-1 expression regulate macrophage viability or commitment to apoptosis during bacterial clearance. J. Clin. Invest. 2005, 115:359-368.
109. Cuconati A., et al. DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes Dev. 2003, 17:2922-2932.
110. Fernando P., Megeney L.A. Is caspase-dependent apoptosis only cell differentiation taken to the extreme?. FASEB J. 2007, 21:8-17.
111. Jang J.H., et al. Preconditioning with death ligands FasL and TNF-alpha protects the cirrhotic mouse liver against ischaemic injury. Gut 2008, 57:492-499.
112. Medzhitov R., et al. Disease tolerance as a defense strategy. Science 2012, 335:936-941.
113. Banno T., et al. Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling. J. Biol. Chem. 2004, 279:32633-32642.
114. Wu N.L., et al. TRAIL-induced keratinocyte differentiation requires caspase activation and p63 expression. J. Invest. Dermatol. 2011, 131:874-883.
115. Li F., et al. Apoptotic cells activate the 'phoenix rising' pathway to promote wound healing and tissue regeneration. Sci. Signal. 2010, 3:ra13.
116. Clarkson R.W., et al. Gene expression profiling of mammary gland development reveals putative roles for death receptors and immune mediators in post-lactational regression. Breast Cancer Res. 2004, 6:R92-R109.
117. Miura M. Apoptotic and non-apoptotic caspase functions in neural development. Neurochem. Res. 2011, 36:1253-1260.
118. Balaban N.Q., et al. Bacterial persistence as a phenotypic switch. Science 2004, 305:1622-1625.
119. Kreso A., et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 2013, 339:543-548.
120. Singh D.K., et al. Patterns of basal signaling heterogeneity can distinguish cellular populations with different drug sensitivities. Mol. Syst. Biol. 2010, 6:369.
121. Almendro V., et al. Cellular heterogeneity and molecular evolution in cancer. Annu. Rev. Pathol. 2013, 8:277-302.
122. Foo J., Michor F. Evolution of acquired resistance to anti-cancer therapy. J. Theor. Biol. 2014, 355:10-20.
123. Jin L., et al. Targeting protein-protein interaction by small molecules. Annu. Rev. Pharmacol. Toxicol. 2014, 54:435-456.
124. Pinto J.P., et al. Targeting molecular networks for drug research. Front. Genet. 2014, 5:160.
125. Ow Y.P., et al. Cytochrome c: functions beyond respiration. Nat. Rev. 2008, 9:532-542.
126. Martinon F., Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ. 2007, 14:10-22.
127. Wajant H., et al. Tumor necrosis factor signaling. Cell Death Differ. 2003, 10:45-65.
128. Barbero S., et al. Identification of a critical tyrosine residue in caspase 8 that promotes cell migration. J. Biol. Chem. 2008, 283:13031-13034.
129. Ehrenschwender M., et al. Mutant PIK3CA licenses TRAIL and CD95L to induce non-apoptotic caspase-8-mediated ROCK activation. Cell Death Differ. 2010, 17:1435-1447.
130. Helfer B., et al. Caspase-8 promotes cell motility and calpain activity under nonapoptotic conditions. Cancer Res. 2006, 66:4273-4278.
131. Kennedy N.J., et al. Caspase activation is required for T cell proliferation. J. Exp. Med. 1999, 190:1891-1896.
132. Lee P., et al. Dynamic expression of epidermal caspase 8 simulates a wound healing response. Nature 2009, 458:519-523.
133. Li F., et al. Apoptotic caspases regulate induction of iPSCs from human fibroblasts. Cell Stem Cell 2010, 7:508-520.
134. Cathelin S., et al. Identification of proteins cleaved downstream of caspase activation in monocytes undergoing macrophage differentiation. J. Biol. Chem. 2006, 281:17779-17788.
135. Brentnall M., et al. Procaspase-3 regulates fibronectin secretion and influences adhesion, migration and survival independent of catalytic function. J. Cell Sci. 2014, 127:2217-2226.
136. Basu S., et al. alpha6 integrin transactivates insulin-like growth factor receptor-1 (IGF-1R) to regulate caspase-3-mediated lens epithelial cell differentiation initiation. J. Biol. Chem. 2014, 289:3842-3855.
137. Droin N., et al. Various functions of caspases in hematopoiesis. Front. Biosci. (Landmark Ed.) 2009, 14:2358-2371.
138. Fernando P., et al. Caspase 3 activity is required for skeletal muscle differentiation. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:11025-11030.
139. Ishizaki Y., et al. A role for caspases in lens fiber differentiation. J. Cell Biol. 1998, 140:153-158.
140. Larsen B.D., et al. Caspase 3/caspase-activated DNase promote cell differentiation by inducing DNA strand breaks. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:4230-4235.
141. Arama E., et al. Caspase activity and a specific cytochrome C are required for sperm differentiation in Drosophila. Dev. Cell 2003, 4:687-697.
142. Kuranaga E., et al. Drosophila IKK-related kinase regulates nonapoptotic function of caspases via degradation of IAPs. Cell 2006, 126:583-596.
143. McCall K., Steller H. Requirement for DCP-1 caspase during Drosophila oogenesis. Science 1998, 279:230-234.
144. Hyman B.T., Yuan J. Apoptotic and non-apoptotic roles of caspases in neuronal physiology and pathophysiology. Nat. Rev. Neurosci. 2012, 13:395-406.
145. Li Z., Sheng M. Caspases in synaptic plasticity. Mol. Brain 2012, 5:15.
146. Williams D.W., et al. Local caspase activity directs engulfment of dendrites during pruning. Nat. Neurosci. 2006, 9:1234-1236.
147. Danial N.N., et al. Homeostatic functions of BCL-2 proteins beyond apoptosis. Adv. Exp. Med. Biol. 2010, 687:1-32.
148. Karbowski M., et al. Role of Bax and Bak in mitochondrial morphogenesis. Nature 2006, 443:658-662.
149. Opferman J.T., et al. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003, 426:671-676.
150. Festjens N., et al. RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ. 2007, 14:400-410.
151. Tourneur L., Chiocchia G. FADD: a regulator of life and death. Trends Immunol. 2010, 31:260-269.
152. Shirley S., Micheau O. Targeting c-FLIP in cancer. Cancer Lett. 2010, 332:141-150.
153. Ozturk S., et al. Cellular FLICE-like inhibitory proteins (c-FLIPs): fine-tuners of life and death decisions. Exp. Cell Res. 2012, 318:1324-1331.
154. Matsuda I., et al. The C-terminal domain of the long form of cellular FLICE-inhibitory protein (c-FLIPL) inhibits the interaction of the caspase 8 prodomain with the receptor-interacting protein 1 (RIP1) death domain and regulates caspase 8-dependent nuclear factor kappaB (NF-kappaB) activation. J. Biol. Chem. 2014, 289:3876-3887.
155. Dillon C.P., et al. Survival function of the FADD-CASPASE-8-cFLIP(L) complex. Cell Rep. 2012, 1:401-407.
156. Martin D.A., et al. Membrane oligomerization and cleavage activates the caspase-8 (FLICE/MACHalpha1) death signal. J. Biol. Chem. 1998, 273:4345-4349.
157. Kischkel F.C., et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995, 14:5579-5588.
158. Boatright K.M., et al. A unified model for apical caspase activation. Mol. Cell 2003, 11:529-541.
159. Donepudi M., et al. Insights into the regulatory mechanism for caspase-8 activation. Mol. Cell 2003, 11:543-549.
160. Barnhart B.C., et al. The CD95 type I/type II model. Semin. Immunol. 2003, 15:185-193.
161. Deveraux Q.L., et al. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997, 388:300-304.
162. Suzuki Y., et al. Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:8662-8667.
163. Deng Y., et al. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev. 2002, 16:33-45.
164. Li S., et al. Relief of extrinsic pathway inhibition by the Bid-dependent mitochondrial release of Smac in Fas-mediated hepatocyte apoptosis. J. Biol. Chem. 2002, 277:26912-26920.
165. Luo X., et al. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998, 94:481-490.
166. Han Z., et al. A sequential two-step mechanism for the production of the mature p17:p12 form of caspase-3 in vitro. J. Biol. Chem. 1997, 272:13432-13436.
167. Chang H.H., et al. Transcriptome-wide noise controls lineage choice in mammalian progenitor cells. Nature 2008, 453:544-547.
168. Feinerman O., et al. Variability and robustness in T cell activation from regulated heterogeneity in protein levels. Science 2008, 321:1081-1084.
169. Spencer S.L., et al. The proliferation-quiescence decision is controlled by a bifurcation in CDK2 activity at mitotic exit. Cell 2013, 155:369-383.
170. Munsky B., et al. Using gene expression noise to understand gene regulation. Science 2012, 336:183-187.
171. Snijder B., Pelkmans L. Origins of regulated cell-to-cell variability. Nat. Rev. 2011, 12:119-125.
172. Spencer S.L., Sorger P.K. Measuring and modeling apoptosis in single cells. Cell 2011, 144:926-939.
173. Pedraza J.M., van Oudenaarden A. Noise propagation in gene networks. Science 2005, 307:1965-1969.
174. Rando O.J., Verstrepen K.J. Timescales of genetic and epigenetic inheritance. Cell 2007, 128:655-668.
175. Hellwig C.T., et al. Real time analysis of tumor necrosis factor-related apoptosis-inducing ligand/cycloheximide-induced caspase activities during apoptosis initiation. J. Biol. Chem. 2008, 283:21676-21685.
176. Purvis J.E., et al. p53 dynamics control cell fate. Science 2012, 336:1440-1444.
177. Nelson D.E., et al. Oscillations in NF-kappaB signaling control the dynamics of gene expression. Science 2004, 306:704-708.
178. Ashall L., et al. Pulsatile stimulation determines timing and specificity of NF-kappaB-dependent transcription. Science 2009, 324:242-246.
179. Paszek P., et al. Population robustness arising from cellular heterogeneity. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:11644-11649.
180. Lee R.E., et al. Fold change of nuclear NF-kappaB determines TNF-induced transcription in single cells. Mol. Cell 2014, 53:867-879.
181. Tay S., et al. Single-cell NF-kappaB dynamics reveal digital activation and analogue information processing. Nature 2010, 466:267-271.
182. Albeck J.G., et al. Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals. Mol. Cell 2013, 49:249-261.
183. Chen J.Y., et al. A two-dimensional ERK-AKT signaling code for an NGF-triggered cell-fate decision. Mol. Cell 2012, 45:196-209.
184. Shankaran H., et al. Rapid and sustained nuclear-cytoplasmic ERK oscillations induced by epidermal growth factor. Mol. Syst. Biol. 2009, 5:332.
185. Yuan T.L., et al. Cell-to-cell variability in PI3K protein level regulates PI3K-AKT pathway activity in cell populations. Curr. Biol. 2011, 21:173-183.